Nanobiotix (NASDAQ:NBTX) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Nanobiotix (NASDAQ:NBTX) has been assigned a "sell (D-)" rating by Weiss Ratings, reflecting negative sentiment towards the stock.
• Despite the poor rating, other brokerages like Leerink Partners and HC Wainwright have issued price targets of $14.00 and maintained a "buy" rating, respectively.
• The stock is currently trading around $19.20, having a fifty-two week low of $2.76 and a high of $30.35, showing significant volatility in price trends.

Nanobiotix (NASDAQ:NBTX - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities researchers at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

Several other brokerages have also recently commented on NBTX. Leerink Partners set a $14.00 price target on shares of Nanobiotix in a research note on Thursday, September 18th. Wall Street Zen upgraded shares of Nanobiotix to a "hold" rating in a research note on Saturday. Finally, HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a research note on Friday, September 19th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Nanobiotix has an average rating of "Hold" and an average price target of $11.00.

Nanobiotix Stock Down 0.4%

Shares of Nanobiotix stock opened at $19.20 on Friday. The company has a fifty day moving average of $15.54 and a 200 day moving average of $8.48. Nanobiotix has a fifty-two week low of $2.76 and a fifty-two week high of $30.35.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.